ACTRN12619000270112已完成未知
An open label randomised controlled trial of Coolsense® versus Buzzy® with wingsversus standard care for Minimising Immunisation Pain of childhood vaccines in Younger children: The MIPY Study.
The Royal Childrens Hospital Foundation0 个研究点目标入组 492 人开始时间: 2019年2月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 492
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 3 Years 至 9 Years（—）
- 性别
- All
入选标准
- •All children aged 3.5 to 9 years of age inclusive presenting with their parents/guardians to the Royal Children’s Hospital Immunisation Service Drop-in Centre forimmunisations.
排除标准
- •Children will be excluded if:
- •1. Child with needle phobia (defined by:fear of medical needleprocedure and/or recent prior failure to vaccinate due to fear/distress of the procedure).
- •2. Child with Haemophilia or other bleeding disorders that require deep subcutaneous injections rather than intramuscular.
- •3. Child with damage to the skin at the site of injection E.G. Overlying Eczema
- •4. Child with developmental/behavioural disorders that may prevent them from being able to complete the Wong Baker Faces scale.
研究者
相似试验
已完成
不适用
Minimising Immunisation Pain of Childhood vaccines: The MIPO StudyPain ManagementAnaesthesiology - Pain managementACTRN12619000258156The Royal Childrens Hospital Foundation492
已完成
4 期
A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health Related Quality Of Life (HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycaemic Agents (OHAs) and high doses of insulin.ISRCTN47355247West Wales Hospital (UK)66
已完成
不适用
An open label, randomized controlled trial of low carbohydrate diet for the comparison of pliotropic effects between breakfast and dinnerType 2 diabetesJPRN-UMIN000010407Kanazawa University Graduate School of Medical Sciences40
进行中（未招募）
不适用
A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination therapy containing DRV/r in HIV-1 infected subjects with undetectable plasma HIV-1 RNA on their current treatments. - NDEUCTR2008-002383-34-ITJANSSEN-CILAG
进行中（未招募）
不适用
A randomised, controlled, open-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination therapy containing DRV/r in HIV-1 infected subjects with undetectable plasma HIV-1 RNA on their current treatments.HIV-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2006-006437-40-ATJanssen-Cilag International NV250